HSV529 Herpes Vaccine Description
HSV529 is a herpes vaccine candidate that is classified as a replication-defective virus, where the virus possesses all the components of the wild-type HSV virus with the exception of two proteins UL5 and UL29 that are involved in viral DNA replication. This replication-defective HSV-2 vaccine can infect cells and should result in a broader immune response. HSV529 uses a replication-defective mutant virus, which is genetically altered to prevent the virus from replicating.
Vaccine-elicited protection against HSV is challenging to achieve due to the ability of herpesviruses to evade many aspects of the mammalian immune response. Subunit vaccines, which consist of individual or small groups of viral antigens, remove the risk of complications resulting from the production of vaccine-associated infectious viral particles but are limited in the degree and scope of immunity that can be produced in vaccinated individuals.
The Sanofi Pasteur vaccine candidate HSV529 is derived from HSV-2 strain 186, which was produced in Vero cells expressing HSV2 UL5 and UL29.
In October 2014, Sanofi Pasteur and Immune Design announced a collaboration: Sanofi Pasteur contributed HSV529, a clinical-stage replication-defective HSV vaccine product candidate, and Immune Design will contribute G103, its preclinical trivalent vaccine product candidate.
On January 10, 2020, a phase 1/2 study, Safety, and Efficacy of 4 Investigational HSV 2 vaccines, evaluating 6 formulations, launched: ClinicalTrials.gov Identifier: NCT04222985.
About Sanofi Pasteur vaccine information.
HSV529 Herpes Vaccine Indication
The HSV529 herpes vaccine candidate is indicated to treat herpes simplex virus (HSV). Worldwide, about 400 million people are infected with herpes simplex virus type 2 (HSV-2), the predominant cause of genital herpes.
Genital herpes is an STD caused by two types of viruses. The viruses are called herpes simplex virus type 1 (HSV-1) and HSV-2.
Genital herpes infection is common in the United States. The CDC estimates that, annually, 776,000 people in the United States get new genital herpes infections.
Of the more than 100 known herpesviruses, 8 routinely infect only humans: herpes simplex virus types 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, human herpesvirus 7, and Kaposi's sarcoma virus or human herpesvirus 8. A simian virus, called B virus, occasionally infects humans. All herpes viruses can establish latent infection within specific tissues, which are characteristic of each virus.
The challenge of developing experimental vaccines that are both safe and effective has led to two opposing approaches in HSV vaccine development: increasing the efficacy of subunit vaccines and increasing the safety of live-attenuated vaccines.
HSV529 Herpes Vaccine Dosage
The HSV529 vaccine candidate was delivered by intramuscular injections (deltoid muscle) as a 0.5 ml solution containing 1 x 10(7) plaque-forming units on day 0, one month after the first dose (day 30), and then six months after the first dose (day 180).
HSV529 Herpes Vaccine Updates
August 7, 2020 - The phase 2 study, 'Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2 (HSV15)' was last updated on September 18, 2020.
January 10, 2020 - Phase 1 and 2 studies were posted. The primary objectives of the studies are: To describe the safety profile of different investigational vaccine regimens against herpes simplex virus type 2 (HSV-2).To evaluate the efficacy of the investigational vaccine regimens with respect to the frequency of herpes simplex virus (HSV) deoxyribonucleic acid (DNA) detection in the genital area (shedding rate) following a 2 dose vaccine schedule; the proportion of participants free of HSV genital recurrence at 6 months after the 2-dose vaccine schedule. Allocation: Randomized 381 participants.
August 2019 - This first-in-human study of the replication-defective HSV vaccine HSV529 showed that it was safe and well-tolerated, with evidence of immunogenicity in HSV-naive and previously infected subjects, and elicited neutralizing antibody and modest CD4+T-cell responses in HSV-seronegative vaccinees.
October 8, 2015 - Phase 1 Clinical Trial for HSV529 Vaccine in HSV-2 Seropositive Adults launches. Last updated on January 14, 2019.
October 16, 2014 - Sanofi Pasteur, the vaccines division of Sanofi and Immune Design Corp., a clinical-stage immunotherapy company, today announced that they have entered into a broad collaboration for the development of a herpes simplex virus (HSV) immune therapy.
HSV529 Herpes Vaccine Clinical Trials
Herpes vaccine news is published by PrecisionVaccinations.com